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Abstract: Gliotoxin (GT), a secondary metabolite produced by Aspergillus molds, has been proposed
as a potential anti-tumor agent. Here we have developed a nanoparticle approach to enhance delivery
of GT in tumor cells and establish a basis for its potential use as therapeutical drug. GT bound
to magnetic nanoparticles (MNPs) retained a high anti-tumor activity, correlating with efficient
intracellular delivery, which was increased in the presence of glucose. Our results show that the
attachment of GT to MNPs by covalent bonding enhances intracellular GT delivery without affecting
its biological activity. This finding represents the first step to use this potent anti-tumor agent in the
treatment of cancer.
Keywords: magnetic nanoparticles; gliotoxin; therapeutic; drug delivery; cancer cells
1. Introduction
Gliotoxin (GT) is a well-known secondary metabolite produced by molds of the
Aspergillus, Penicillium, Gliocladium, and Trichoderma families. It belongs to the group of
epipolithiodioxopiperazines (ETP) [1] that are mycotoxins characterized by the presence of a disulfide
bridge in their structure, responsible for their biological activity [2]. Among the different members
of this family, GT has been the best characterized and most extensively studied, since its discovery
in 1932 [3–6]. It was initially described as an anti-microbial toxin produced by Penicillium spp. [7,8].
Later on, it was shown to be a potent immunosuppressive factor synthesized by Aspergillus
fumigatus [9–13], the most ubiquitous species within the Aspergillus genus and most common causative
agent of the lethal opportunistic infection Invasive Aspergillosis (IA). GT synthesis is carried out by
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specific genes, involved in several metabolic pathways, and its production is tightly regulated by
mold specific thiol methylases that produce the methyl inactive derivative, bismethylthiogliotoxin
(bmGT) [14,15]. In line with its immunosuppressive and toxic effects on the host, GT was characterized
as a virulence factor of Aspergillus fumigatus [16] and its inactive metabolite bmGT has been proposed
as a diagnosis biomarker for IA [14,17,18].
As mentioned above, GT is a potent immunosuppressant that affects normal functioning of both
the innate and adaptive immune response in vitro and in vivo. It has been shown that GT inhibits
phagocytosis, inflammation, neutrophil activation, monocytes, dendritic cell and antigen presentation,
and T and B cell activation [19–22]. In addition, GT has been extensively studied as anti-fibrotic,
anti-angiogenic, anti-proliferative, and pro-cell death factor [20,23]. Indeed, GT has been proposed as
a potent anti-tumor agent that activates both apoptotic and necrotic death pathways in target cells by a
mechanism dependent on its redox modulatory activity. The disulfide bridge present in GT is able to
interact with thiol groups on proteins initiating the production of reactive oxygen species (ROS) which
lead to mitochondrial membrane disruption, DNA damage and cell death [24–29]. Apart from its
ability to directly activate cell death, GT has been proposed to inactivate molecular pathways involved
in cell proliferation like NFkB [30,31], NOTCH [32], WNT [33], or fanesyl transferases. In addition,
it has been proposed as a good drug candidate for the treatment of autoimmune and inflammatory
diseases like colitis or arthritis [34–36], transplant tolerance [37], and as an anti-cancer compound.
However, GT, as other immunomodulatory and chemotherapeutic agents, is also toxic for healthy
tissues and cells and its use for the treatment of human disease has not been further developed.
A protocol that would specifically deliver GT to affected cells would reduce exposition of healthy
tissue to this toxin and would allow exploiting its biological activity for the treatment of human disease.
For that reason, we have used biocompatible MNPs as carriers. MNPs are usually composed of an
inorganic core and an organic shell. The inorganic core very often consists of magnetite and maghemite
(Fe3O4, γ-Fe2O3), the most common forms. The organic shell, located in the most external part of the
MNP, provides the chemical functionality and is responsible for the solubility, stability, charge effect,
and interactions with other molecules. These MNPs have obtained significant attention owing to their
biocompatibility and relatively low toxicity [38,39]. Furthermore, MNPs can be covalently conjugated
to biological molecules and to surface coatings e.g., poly (ethylene glycol) (PEG) or carbohydrates.
PEG [40] confers hydrophilicity, increasing their solubility in water, and also prevents MNP aggregation
and non-specific binding with other molecules. Carbohydrate [41] functionalization modulates cellular
uptake for specific recognition or interaction with glucose transporters, which are overexpressed in
tumor cells. Glucose is the most common carbohydrate that acts as a selective carrier.
Here we have analyzed the potential of using biocompatible MNPs, functionalized with
fluorescent dyes and glucose to enhance GT delivery into tumor cells and simultaneously monitor
intracellular delivery.
We have found it is possible to bind GT to biocompatible MNPs in the presence of specific delivery
agents like glucose, modulating its internalization and retaining a good biological activity. Thus,
pending of further studies to characterize the in vivo efficacy and safety of these novel nanoconjugates,
our findings reveal a novel approach to take advantage of the pharmacological activity of GT, increasing
the stock of fungal secondary metabolites for the treatment of human disease.
2. Materials and Methods
2.1. Synthesis of MNPs
Synthesis of monodisperse MNPs (nominal diameter of 6–8 nm) was carried out following the
seed-mediated growth method reported by [42]. The resulting MNPs were transferred into water
by using an amphiphilic polymer [43]. Briefly, 250 mg of poly(maleic anhydride-alt-1-octadecene)
(PMAO) was added to a flask containing 200 mL of chloroform. After the polymer was completely
dissolved under magnetic stirring, 20 mg of nanoparticles were dropped, and the mixture was sonicated
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for 15 min. The solvent was removed under vacuum, and then the polymer coated MNPs were
resuspended in 20 mL of NaOH 0.05 M. The MNPs were purified by centrifugation at 25,000 rpm
for 2 h and characterized by transmission electron microscopy (TEM, under a 200 kV transmission
electronmicroscope FEI Tecnai TF20 (FEI Europe, Eindhoven, Netherlands).
2.2. Functionalization of MNPs with Gliotoxin
To attach the gliotoxin (GT) or its bismethylated analogue (bmGT) to the MNPs, as shown in
Scheme 1, the toxins were first modified with N-(p-maleimidophenyl) isocyanate (PMPI, Thermo
Fisher, Waltham, MA, USA) and cysteine (Cys, Sigma Aldrich, St. Louis, MO, USA). For the first
step, 1.5 µM of PMPI and 0.3 µM of GT/bmGT were mixed in 132 µL of DMSO and left stirring for
2 h at room temperature. Then, 10 µL of methanol were added to block the unreacted isocyanate
groups (PMPI-GT/bmGT). After that, PMPI-GT/bmGT was incubated with 3 mol of cysteine dissolved
in 20 µL of 50 mM phosphate buffer pH 6.5 for 1 h at room temperature (Cys-PMPI-GT/bmGT).
The efficacy of the reaction was monitored by the Ellman’s assay determining the decrease of the
concentration of free thiol groups in the sample.
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Scheme 1. (a) Chemical structure of gliotoxin and bismethylthiogliotoxin; (b) Schematic representation
of magnetic nanoparticles (MNPs) functionalization using EDC/NHS chemistry.
In a common functionalization 1 mg of MNPs were mixed with 8 µM of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, Sigma Aldrich) and 10 µM of
either α-metoxy-ω-aminopolyethyleneglycol (H2N-PEG-OMe 750 Da, Iris Biotech, Marktredwitz,
Germany) (MNPs/PEG) or 10 µM of 4-aminophenyl-β-D-glucopyranoside (Sigma Aldrich)
(MNPs-Glu) in 450 µL of 50 mM borate buffer pH 9. After incubating the mixture for 15 min at room
temperature, 8 µM of EDC and 0.03 µM of 5(6)-TAMRA (tetramethylrhodamine-5-carboxamide)
cadaverine (Anaspec, Fremont, CA, USA) were added and left stirring for 2 h followed by a washing
step with phosphate buffered saline (PBS) and Tween 20 at 0.1% (w/v). Then, 25 µM of Tris (Sigma
Aldrich) were added to block the remaining carboxylic groups on the MNPs and left stirring overnight
at 4 ◦C.
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Finally, 0.5 mg of purified MNPs (MNPs-PEG or MNPs-Glu) were mixed with a solution
containing 11.7 µM of EDC and 20.7 µM of N-hydroxysulfosuccinimide (sulfo-NHS, Sigma Aldrich)
in 1 mL of 10 mM MES buffer pH 6 and incubated for 30 min at 37 ◦C. After that, the excess of
EDC and sulfo-NHS was removed by using a PD-10 desalting column (GE Healthcare, Chicago,
IL, USA). The activated MNPs were then incubated with the complex previously prepared
(Cys-PMPI-GT/bmGT) and 50 mM borate buffer pH 9 up to a final volume of 500 µL and left stirring
for 2 h at room temperature. Lastly, the rest of the activated carboxylic groups were blocked with
20 µL of Trisbuffer 3 M and the mixture was incubated overnight at 4 ◦C (GT/bmGT-MNPs).
The final GT/bmGT-MNPs were purified by centrifugation with Amicon® centrifugal filters
(Merck KGaA, Darmstadt, Germany) 100 kDa cut off) and characterized by TEM, Elman’s assay and
agarose electrophoresis.
2.3. Characterization of MNPs
TEM analysis. 10 µL of the aqueous solution of MNPs was placed on a copper grid coated with a
carbon film. The grid was left to dry in air and the TEM images were obtained by using a Tecnai T20
(FEI, Hillsboro, OR, USA) electron microscope model working at 200 kV.
Agarose Electrophoresis. 1% (w/v) agarose gels prepared in 0.5X Tris-Borate-EDTA buffer (TBE).
The samples were loaded by mixing with 30% of glycerol and allowed to run for 10–20 min at 100 V.
Ellman’s assay. The free thiol groups react with DTNB (5,5′-dithio-bis(2-nitrobenzoic) acid) to
give a colored product 2-nitro-5-thiobenzoate (TNB) that can be measured spectrophotometrically. In
the optimal conditions, 50 µL of sample solution were mixed with 225 µL of phosphate buffer 0.1 M
pH 8 and 5 µL of DTNB 4 mg/mL. The mixture was made to react for 15 min and the absorbance at
405 nm was measured. The linear range for the thiol group was 0–1.5 mM (Abs405 = 1.8934 [SH, mM]
+0.0186.
2.4. Cell Culture and Reagents
L929 (Mouse fibrosarcoma) cell lines were used [44]. Cells were cultured with Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), L-glutamine 2 mM
(Gibco) and 1% antibiotics (penicillin 100 U/mL – streptomycin 100 µg/mL, Sigma-Aldrich). All cell
lines were maintained at 37 ◦C under a humidified atmosphere with 5% CO2. Only cells with viability
higher than 90% were used in the experiments.
GT and bmGT were purchased from Enzo Life Tech., Farmingdale, NY, USA.
2.5. Cell Viability, Cell Proliferation, and Cytotoxicity Assay
Cells (104 cells/mL) were seeded in 96 well plates (100 µL/well) to get attached to the bottom.
The following day, cells were incubated overnight with different concentrations of GT/bmGT or MNPs
functionalized to analyze proliferation and cytotoxicity.
Cell viability was evaluated by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay as described previously [45]. All experiments were run in triplicate and repeated
at least three times. IC50 (the concentration of compound required to reduce cell survival to 50%)
was obtained by linear regression analysis of the dose-response curve plotting concentration (X axes)
versus percentage of viability (Y axes) according to the following formula:
%V = Abs(cells) − Abs(medium) × 100 (1)
Quantification of cell death and apoptosis was carried out using two different parameters,
Phosphatidylserine (PS) exposure and membrane permeabilization by using Annexin V (AnnV) and
7-Aminoactinomycin D (7AAD) staining. Cells were analyzed by Flow Cytometry (FACS) employing a
FACS Calibur instrument (BD Pharmingen, Franklin Lakes, NJ, United States) and CellQuests software
version 6.0 (BD). Briefly, cells were incubated in 100 µL Annexin binding buffer (ABB) with 1 µL
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Annexin V-FITC (Inmunostep) and 1.5 µL 7AAD (BD) for 15 min at room temperature. For the analysis
cells were washed with PBS and fixed with 1% (v/v).
2.6. Flow Cytometry
For quantification of intracellular uptake of TAMRA labelled MNPs, L929 cells (104 cells/well)
were incubated with MNPs at a final concentration of 10 µM in a 96 well plate (100 µL/well).
After different incubation times, cells were trypsinized and washed with PBS to remove
not internalized MNPs bound to extracellular cell membrane. Afterwards cells were fixed in
paraformaldehyde (PFA) 1% for 30 min at 4 ◦C. All experiments were repeated three times for
each group.
2.7. Confocal Microscopy
Cells were seeded on 5 mm diameter microscopy cover slides (Electron Microscopy Sciences,
Hatfield, PA, USA) placed in 96 well plates and treated under the same conditions as before.
At selected times, slides were washed with PBS and cells were fixed with 4% PFA for 20 min at
4 ◦C. Coverslips were taken out and cells were permeabilized and washed with 0.1% saponin in PBS,
PBS and deionized water following the incubation with Lamp1 (rat, BD) (1:500) and cytochrome c
antibody (mouse, BD) (1:100) in 0.1% saponin and 10% goat serum for 1 h at room temperature in
darkness. Cells were washed again and incubated with the secondary antibody Rat-Alexafluor488
(goat, Invitrogen) (1:500) and Mouse-Alexa633 (goat, Invitrogen) (1:250) for 30 min at room temperature.
Then slides were air-dried and mounted on a drop of fluoromount-G (Southern Biotechnology
Associates, Inc., Birmingham, AL, USA) containing 20 µg/mL of nuclear staining Hoechst 33342
(Molecular ProbesTM). Next, the cells were analyzed by confocal microscopy. Fluorescence images
were taken on a confocal microscope using 60X oil immersion objective (Olympus FV10-I, Waltham,
MA, USA). Data was analyzed using the software FV10i-SW Viewer v3.1 (Olympus) with the same
settings for all the samples.
2.8. Transmission Electron Microscopy
For TEM analysis L929 cells (2 × 104 cell/well) were plated on 4 well chamber slides with
permanox (Nunc-Thermo Fisher Scientific, Waltham, MA USA), washed three times in PBS, fixed with
2.5% glutaraldehyde in 0.1 M phosphate buffer (PB) for 2h at 4 ◦C and finally washed with 0.1 M PB
for four times. After, samples were processed for TEM as described in [46].
2.9. Statistics
Statistical analyses were performed using GraphPad software version 7. A one-way ANOVA
with Bonferroni post-test was performed comparing the different groups with control cells.
In all cases, statistically significant difference was determined as *(p < 0.05), **(p < 0.01) and
***(p < 0.001) respectively.
3. Results and Discussion
3.1. Characterization of Magnetic NPs Functionalized with GT and Inactive bmGT
MNPs were synthesized in organic media by thermal decomposition and efficiently transferred to
aqueous phase by using an amphiphilic polymer (PMAO). To differentially modulate cell MNP uptake
and monitoring its internalization, they were further functionalized with either PEG or glucose and a
fluorescent marker (TAMRA). This type of MNPs have been used in our group since 2008 and they
have been extensively characterized previously as indicated in [41,47–49]. The attachment to the GT or
the inactive derivative bmGT was made in a stepwise procedure using the bifunctional linker PMPI
and cysteine (Cys-PMPI-GT/bmGT). The effectiveness of this coupling relied on the reaction of the
sulfhydryl group of the cys with the maleimide of the PMPI, which could be followed by Ellman’s
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assay showing an important decrease in the signal due to the smaller amount of free thiols in the
sample. We have previously shown that this type of assay is suitable to quantify the free thiols in this
type of MNPs and there are not interferences between MNP and Ellman’s assay [50].
Then this complex was attached to the MNPs through the amide formation between the free
amine on cys and the carboxylic groups exposed on the MNPs. To ensure an effective functionalization,
the stability of the MNPs was confirmed by TEM (Figure 1a) and the variations of their net charge
due to replacing some carboxylic groups by GT/bmGT were analyzed by agarose electrophoresis
(Figure 1b).
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Finally, a similar strategy was followed in order to quantify the amount of GT or bmGT attached
to the final MNPs. To do so, the functionalization was done in the same way, but cys was attached
directly to the MNPs and then coupled with the complex PMPI-GT/bmGT. So, 200 µM of GT/bmGT
turned out to be successfully attached to the MNPs as determined by the reduction of free thiol groups
on the MNPs by Ellman’s assay (Figure 1c).
3.2. Magnetic NPs Functionalized with GT Kill L929 Sarcoma Cells
To assess the potential of employing GT-functionalized MNPs to kill tumor cells we used the
mouse sarcoma model L929, a mouse cell model previously found to be sensitive to soluble GT [17].
First of all, we calculated the IC50 dose of GT by MTT assay in order to have a control value to
compare with the activity of GT after MNP functionalization. Cells were incubated over a range of
concentrations between 0.1 and 1 µM for 16 h (Figure 2a). We can observe a dose dependent GT toxicity
with a calculated IC50 value of 200 nM. In contrast, most cells treated with 1 µM inactive bmGT as
control, remained viable after overnight incubation.
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Figure 2. Effect of exposures to gliotoxin on the viability of L929 cell line. (a) L929 cells were exposed to
different concentrations, i.e., 0.06, 0.125, 0.25, 0.5, and 1 µM of GT at 37 ◦C overnight. Cell viability was
measured using MTT assay. The IC50 values indicated in the text were determined by extrapolation,
which were presented as mean ± SEM of three independent experiments. (b) A representative dot plot
is shown. Cell death was analyzed by FACS monitoring AnnV and 7AAD under the same conditions
as before with 0.5 µM of GT.
Since MTT assay measures cell proliferation, we analyzed if cells incubated with GT died by
monitoring phosphatidylserine (PS) translocation and membrane integrity by Annexin-V binding and
7AAD uptake assays, respectively. As shown in Figure 2b, L929 cells incubated with 0.5 µM of GT
were positive for AnnV and 7AAD staining confirming that GT actually kill L929 cells. Moreover, the
IC50 values calculated by MTT and cell death assays were similar (data not shown).
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Once we confirmed that GT, but not bmGT, killed L929 cells, we analyzed if GT bound to
GT-MNPs was still able to kill L929 sarcoma cells. First of all, we confirmed that non-functionalized
MNPs were not toxic for L929 cells (data not shown). As shown in Figure 3a, GT bound to MNPs
was able to block survival of L929 cells in a dose dependent manner confirming that GT retained
anti-tumor activity after binding to MNPs. The results obtained employing the MTT survival assay
were confirmed by analyzing Trypan Blue exclusion assay. As shown in Figure 3b, GT-MNPs killed
L929 cells in a dose dependent manner. In contrast, bmGT-MNPs had no effect against L929 cells at the
highest concentration neither by MTT survival assay nor by Trypan blue exclusion cell death assay.
These results confirm that functionalization of MNPs with GT generates a nanoconjugate system with
specific anti-tumor activity in L929 sarcoma cells. We have also analyzed the ability of GT-MNPs to
kill other cell types like breast carcinoma MCF-7 or cervix carcinoma HeLa. However, these tumor
types are much more resistant to free GT (IC50 values around 1 µM, data not shown) and, thus, it
was required up to 20 µM of GT-MNPs to see any effect on cell proliferation. This data suggests that
although GT retains anti-tumor activity in vitro against sarcoma L929 cells, its potential application to
other tumor types might be more limited.
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Figure 3. Biocompatibility of different functionalized nanoparticles with L929 cells. L929 cells were
incubated with MNPs functionalized with GT, GT and glucose, and GT and PEG, respe tively at
different concentrations (1.25, 2.5, 5 and 10 µM) overnight at 37 ◦C. Subseque tly, cells wer washed
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c ntrol. (a) Quantification of cell viability was carri d out by MTT as indicated in experimental
pr cedures. The IC50 values were determined by extrap la ion, which were presented as mean ±
SEM of three independent experiments. Statistical analysis between MNPs functionalized with GT
and GT/glucose was performed using paired t test. *, 0.01 < p < 0.05. (b) Analysis of the effect
of GT-MNPs, glucose-conjugated GT-MNPs and PEG-conjugated GT-MNPs on the cell viability of
L929 cells by Trypan Bl e by microscopy. Data are express as the mean values ± SEM of three
separate experiments.
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3.3. Glucose Enhances the Anti-Tumor Activity of Magnetic NPs Functionalized with GT against L929
Sarcoma Cells
In order to modulate the selectivity of GT-MNP conjugate against tumor cells we analyzed if
glucose, known to enhance the uptake of MNPs in tumor cells [47], would increase the ability of
GT-MNPs to kill L929 sarcoma cells. As control, the cytotoxic activity of GT-MNP functionalized with
glucose (GT-MNPs-Glu) was compared with PEGylated GT-MNPs (GT-MNPs-PEG). As shown in
Figure 3a, inhibition of L929 cell proliferation was significantly higher in GT-MNPs-Glu-treated
cells than in those treated with GT-MNPs. A similar result was found when cell death was
analyzed by trypan blue exclusion assay (Figure 3b). In contrast, incorporation of PEG into GT-NPs
completely abrogated the anti-tumor effect of GT-MNPs. Again, the cytotoxic potential of MNPs-Glu
functionalized with bmGT was almost completely reduced, confirming that this effect was due to
GT presence.
Our results agree with previous findings indicating that PEGylation modifies the size of the
particle and prevents intracellular delivery [43]. In contrast, due to changes in the metabolic status,
glucose would favor intracellular uptake of MNPs in L929 tumor cells enhancing intracellular delivery
of GT and its ability to kill tumor cells. This result agrees with previous reports in which glucose
enhanced the uptake of gold NPs in other types of tumor cells [46,51].
3.4. Glucose Enhances Cellular Interaction of Magnetic NPs Functionalized with GT in L929 Sarcoma Cells
Once we have confirmed that Glucose functionalization enhanced the ability of GT-MNPs
conjugates to kill L929 cells, we analyzed if this effect correlated with intracellular uptake of MNPs. To
this aim the different MNP conjugates were functionalized with TAMRA and intracellular uptake in
L929 cells analyzed by flow cytometry.
As shown in Figure 4b, after incubation with the different MNP conjugates most cells were
positive for TAMRA fluorescence after 30, 60 or 240 min, indicating interaction of MNPs with cells,
irrespectively of the presence of GT, bmGT, and/or glucose. However, when the level of single cell
fluorescence intensity (MFI) was analyzed and represented (Figure 4a), it was found that cellular
uptake was significantly enhanced by the presence of glucose after 4h. In contrast, the presence of
GT and bmGT has no effect on MNP uptake. The same number of cells was recovered at the end of
the incubation time indicating that the differences in fluorescence intensity were not due to a lower
number of cells.
Notably, PEG almost completely abrogated the uptake of MNPs. These results agree with the
ability of the different MNP conjugates to kill L929 cells (Figure 3) and confirm that glucose enhances
cell uptake of MNPs in L929 cells and the ability of GT-MNPs to kill these types of tumor cells.
This result agrees with previous experimental findings [43,52], showing that PEG prevent NP uptake,
suggesting that that the lack of GT toxicity using MNPs-PEG might be related to its inability to enter
into cells [53]. Hence, these MNPs were excluded from the study.
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Figure 4. Uptake kinetics of MNPs. L929 cells were incubated with MNPs or MNPs functionalized with
GT/bmGT, GT/bmGT (bismethylthiogliotoxin) and glucose, or GT/bmGT and PEG at a concentration
of 10 µM for different incubation times at 37 ◦C. Subsequently, cells were rinsed 3 times with PBS
and fixed in PFA 1%. (a) Mean fluorescence intensity was analyzed by flow cytometry FACS. Graph
represents the mean fluorescence intensity of three independent experiments. Statistical analysis was
performed using one-way ANOVA with Bonferroni comparing with GT or bmGT as control. **, p < 0.01
(b) Histograms show the mean fluorescence intensity of a representative experiment: untreated cells
(black) versus incubated with or without glucose (red). The percentage of cells was determined by
flow cytometry.
3.5. Glucose Enhances Intracellular Delivery of Magnetic NPs Functionalized with GT in L929 Sarcoma Cells
Next, we confirmed by using confocal microscopy if MNPs were internalized and colocalized
with the late endosomal/lysosomal marker Lamp-1. As shown in Figure 5, after 4 h of incubation,
cells had internalized the different types of MNPs confirming that they were able to entry L929
cells and the results obtained by flow cytometry. However, as found in flow cytometry, the degree
of internalization varied dependent on the presence of glucose. All MNPs functionalized with
glucose were internalized by cells, presenting a clear pattern of intracellular fluorescence after 4 h.
In contrast, differential interference contrast (DIC) images revealed that extracellular MNPs were
visible in those cell cultures treated with MNPs that do not contain glucose (not shown), confirming
the flow cytometry data. In addition, in those cells that internalized glucose-functionalized MNPs the
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presence of TAMRA colocalized with the lysosomal Lamp-1 marker creating a yellow fluorescence
pattern. This co-localization was lost when free MNPs (without GT/bmGT and glucose) were used.
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Figure 5. Localization of MNPs by confocal microscopy. L929 cells were incubated with MNPs or 
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Figure 5. Localization of MNPs by confocal microscopy. L929 cells were incubated with MNPs or
MNPs (10 µM) functionalized with GT, bmGT, GT and glucose, or bmGT and glucose for 4 h at 37
◦C. Subsequently, cells were washed and fixed with PFA4% and stain d with Hoechst 3342 (DNA
marker) and anti-Lamp1 (lysosome marker) followed by a sec ndary Alexa 488 labelled antibody
as indicated in materials and methods. Fluorescence images were taken on a confocal microscope.
The overlap shown MNPs internalized (white asterisks) and non-internalized MNPs (white arrows).
Higher magnifications (zoom) are shown. Scale bar = 50 µm.
Fluorescence MNP did not localize with the mitochondrial marker cytochrome c (data not
shown) or with nuclear marker Hoechst (Figure 5) indicating that they were not associated to these
organelles. Moreover, some free MNPs that were internalized by some cells did not localize with
lysosomes indicating a completely different internalization route. Finally, incubation of cells at 4 ◦C
prevented killing of L929 cells and internalization of all types of MNPs confirming an energy-dependent
mechanism (Figure 6).
Although it has been previously found that soluble GT uptake is enhanced in comparison with
inactive bmGT [54], our results seems to indicate that the presence of GT or bmGT does not influence
MNP uptake (compare GT-MNPs, bmGT-MNPs, and MNP uptake, Figure 4). Likely the presence
of MNPs and glucose seems to be a key factor that modulates entry in L929 cells. These apparent
contradictory findings could be explained by a preferential effect of glucose versus GT during the
internalization of MNPs when both are present. Indeed, glucose is known to be a strong signal for
MNP internalization in tumor cells [55,56] and it is commonly used as selective biomarker in clinics to
monitor tumor progression and metastasis [57].
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Figure 6. Energy-dependent endocytic uptake of MNPs. (a) L929 cells were incubated with MNPS
or MNPs functionalized with GT/ bmGT or GT/ bmGT and glucose at a concentration of 10µM
overnight at 4 ◦C. Subsequently, L929 cells were washed with PBS and cell viability was analyzed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Values are presented as
mean ± SEM of two independent experiments. (b) Cells were incubated with TAMRA labelled MNPs
(10 µM) and GT, bmGT, GT and glucose, and bmGT and glucose. For control experiment, cells were
incubated with non-functionalized MNPs. Subsequently, mean fluorescence intensity was analyzed by
FACS. Graph represents the mean fluorescence intensity of two independent experiments.
Our results agree with previous findings employing gold NPs in which glucose also enhanced
intracellular NP delivery in a variety of tumor cells including pancreas, lung, melanoma or cervix [46].
However, it should be taken into account that the level of internalization of free NPs or glucose
functionalized NPs depends on the type of target cells as well as the type of NPs employed [58]. Thus,
this might be a good strategy to deliver GT on tumor cells highly dependent on glucose but might not
work for selective delivery in other tumors or cells with low glucose addition.
To finally confirm that glucose functionalized MNPs were located in lysosomes and find out
whether the presence of glucose affected the intracellular location of GT/bmGT functionalized MNPs,
we analyzed intracellular delivery of the different MNPs by TEM. As shown in Figure 7, MNPs
functionalized with glucose showed a similar behavior and intracellular location independently on
the presence of GT or bmGT. Indeed, they were localized in dense lysosome-like structures (late
endosomes/lysosomes) confirming the confocal microscopy data. In contrast, MNPs functionalized
with GT/bmGT without glucose were located in white vacuole-like structures indicating an effect
of glucose not only on the level of internalization, but in addition, in the uptake route. Notable, free
MNPs were located in similar structures confirming that in this type of cells the presence of GT or
bmGT do not affect intracellular MNP delivery, which seems to be modulated by glucose. Analyses by
scanning transmission electron microscope (STEM) confirmed that the lysosomal or vacuole associated
material contained iron and, thus, corresponded to iron magnetic NPs.
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with GT/ bmGT or GT/ bmGT and glucose at a concentration of 10 µM for 4 h at 37 ◦C. Subsequently,
L929 cells were fixed with glutaraldehyde and processed for TEM as described in Materials and
Methods. NPs were observed in the lysosomes or vacuoles. (b) The detection of iron traces through
chemical composition analysis by STEM confirmed the presence of NPs inside cells. Representative
pictures are shown.
4. Conclusions
Gliotoxin (GT) is a potent fungal mycotoxin with a great variety of biological activities including
anti-tum r. A novel nanoconjugate consisting of magnetic NPs functionalized with Glucose, th
fungal mycotoxin GT and TAMRA was developed and fou d t be active against mouse sarcoma cells.
The presenc of glucose enhances intracellular uptake and lysos mal localization of GT-functionalized
NPs, which correlates with a higher cytotoxic potential against L929 sarcoma cells. Although “normal”
cells also require glucose and, thus, they might incorporate NP functionalized with GT and glucose,
the clinical data employing radioactive labelled glucose show that normal cells and tissues accumulate
much lower amount of glucose than cancer cells [57]. Pending of the in vivo toxicology studies that will
be further required to analyze if the amount of GT-NPs accumulated by normal cells will be enough to
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cause toxicity (the next logical step to further support the feasibility of the clinical application of GT
nanoconjugates), our results for the first time show that it is feasible to deliver biologically active GT on
tumor cells employing NPs. These findings establish the first rational basis to employ similar strategies
to deliver biologically active GT on NPs to other types of cells, employing cell specific ligands, with
potential application to cancer as well as other pathologies like autoimmunity or transplantation.
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